

# Reimbursement Guide

## About Cardea SOLO™

Cardea SOLO is a wearable single-use ECG Sensor and Software System for Short-Term (up to 48 hours) or Long-Term (up to 7 days) Electrocardiographic Monitoring. Cardea SOLO provides clinicians with ECG waveform analysis capabilities and comprehensive patient data that can assist in cardiac arrhythmia diagnosis at the point of care.



## Cardea SOLO Indications for Use

Cardea SOLO is indicated for use on adult patients who may be asymptomatic or who may suffer from transient symptoms such as palpitations, dizziness, anxiety, fatigue, syncope, pre-syncope, light-headedness, shortness of breath or who are at risk of developing atrial fibrillation and where a software-assisted analysis of an ambulatory ECG could identify potential cardiac causes of these symptoms. It includes a prescription only, single-use, continuous ECG recorder that can be worn up to 7 days during activities of daily living.

Always refer to Cardea SOLO user documentation for important information on intended use, contraindications, technical performance specifications and detailed operating instructions.

### Disclaimer

Information provided in this document is for convenience and general information purposes only. It is obtained from publicly available, third-party sources and is subject to error, omission or change without notice due to complex and frequently changing laws, regulations, rules and policies. Cardiac Insight makes no representation, statement, promise or guarantee of coverage or levels of reimbursement. Payments will vary by geographic location and payor. Always refer to the patient's insurance plan and/or the local Medicare Administrative Contractor for Local Coverage Determinations (LCDs) and for any additional requirements and guidance for coding, coverage and payment.

<sup>1</sup>CPT Copyright 2023 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Cardea SOLO™ is a trademark of Cardiac Insight Inc. All product names, logos, and brands are property of their respective owners. All company, product and service names used in this document are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

<sup>2</sup>CMS-1772-F, Medicare Physician Fee Schedule for CY 2023

<sup>3</sup>National Average from the 2023 Centers for Medicare and Medicaid Physician Fee Schedule and the Hospital Outpatient Prospective Payment Schedule. Amounts do not reflect adjustments for geographical differences.

## ICD-10-CM Diagnosis Codes

Accurate and thorough ICD-10-CM diagnosis code(s) documentation can support medical necessity for Cardea SOLO use. Include all appropriate ICD-10 diagnosis codes and supporting clinical documentation.

Always check with your local payers and Medicare Administrative Contractor for covered ICD-10 codes, other specific requirements and policy updates.

The following ICD-10-CM codes and/or ranges may assist in the clinical decision process:

ICD-10-CM	ICD-10-CM Diagnosis Code/Range
<b>I45.9</b>	Conduction disorder, unspecified
<b>I47.1</b>	Supraventricular tachycardia
<b>I47.2</b>	Ventricular tachycardia
<b>I47.9</b>	Paroxysmal tachycardia
<b>I48.0</b>	Paroxysmal atrial fibrillation
<b>I48.11</b>	Longstanding persistent atrial fibrillation
<b>I48.19</b>	Other, persistent atrial fibrillation
<b>I48.20</b>	Chronic atrial fibrillation, unspecified
<b>I48.21</b>	Permanent atrial fibrillation
<b>I48.3</b>	Typical atrial flutter
<b>I48.4</b>	Atypical atrial flutter
<b>I48.91</b>	Unspecified atrial fibrillation
<b>I48.92</b>	Unspecified atrial flutter
<b>I49.1</b>	Atrial premature depolarization
<b>I49.01</b>	Ventricular fibrillation
<b>I49.02</b>	Ventricular flutter
<b>I49.3</b>	Ventricular premature depolarization
<b>I49.40</b>	Unspecified premature depolarization
<b>I49.49</b>	Other premature depolarization
<b>I49.5</b>	Sick sinus syndrome
<b>I49.8</b>	Other specified cardiac arrhythmias
<b>I49.9</b>	Cardiac arrhythmia, unspecified
<b>I63.9</b>	Cerebral infarction, unspecified
<b>R00.1</b>	Bradycardia, unspecified
<b>R00.2</b>	Palpitations
<b>R42</b>	Dizziness and giddiness [light-headedness]
<b>R55</b>	Syncope and collapse
<b>R56.01</b>	Complex febrile convulsions

The ICD-10-CM is copyrighted by the World Health Organization (WHO), which owns and publishes the classification.

## CPT®† and APC Codes

The CPT code set describes medical, surgical, and diagnostic services. It communicates uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial and analytical purposes.

CPT Category I codes are used for reporting devices and drugs (including vaccines) required for the performance of a service or procedure, services or procedures performed by physicians and other health care providers, services or procedures performed intended for clinical use, services or procedures performed according to current medical practice, and services or procedures that meet CPT requirements.

APCs are an outpatient prospective payment system applicable only to hospitals.

Cardea SOLO supports reimbursement using Category I codes in both the in-office and hospital setting and for short- and long-term external electrocardiographic (ECG) monitoring needs.

Continuous Short-Term ECG Monitoring Up to 48 Hours (e.g., Holter Monitoring)			2023 National Unadjusted Averages <sup>2</sup>	
CPT Code	APC Category	Description	RVUs (CPT)	Facility (APC)
<b>93224</b> (Global)	N/A	External electrocardiographic recording for <b>up to 48 hours</b> by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	2.17	
<b>93225</b>	<b>5734</b>	Recording (includes connection, recording and disconnection)	0.55	\$116.11
<b>93226</b>	<b>5734</b>	Scanning analysis with report	1.08	\$116.11
<b>93227</b>	N/A	Review and interpretation	0.54	

Continuous Long-Term ECG Monitoring More Than 48 Hours Up to 7 Days			2023 National Unadjusted Averages <sup>2</sup>	
CPT Code	APC Category	Description	RVUs (CPT)	Facility (APC)
<b>93241</b> (Global)	N/A	External electrocardiographic recording for <b>more than 48 hours up to 7 days</b> by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	7.89	
<b>93242</b>	<b>5732</b>	Recording (includes connection, recording, and disconnection)	0.36	\$33.96
<b>93243</b>	<b>5734</b>	Scanning analysis with report	6.84	\$116.11
<b>93244</b>	N/A	Review and interpretation	0.69	

## Medical Necessity Documentation

Documenting the clinical rationale for prescribing Cardea SOLO is an important step to support the reimbursement process. The following are suggested documentation considerations for the patient record:

Documentation element	Suggested inclusion and rationale
<b>Frequency of symptom occurrence</b>	Patient's relevant symptoms and pertinent medical history
<b>Prior tests results</b>	Document why prior test results may be inconclusive or insufficient, particularly any previous cardiac monitoring tests
<b>Rationale for long-term monitoring if &gt; 48 hours</b>	Document if applicable and indicated
<b>'Rule in/Rule out' diagnoses and/or suspected diagnostic implications</b>	Document anticipated contribution of Cardea SOLO test results to patient's diagnosis and treatment plan
<b>Expected level of patient compliance with short- and long-term ECG monitoring</b>	Document expected patient compliance capability to adhere to Cardea SOLO testing Sensor wear and care requirements

## Clinical Documentation Using Cardea SOLO Analysis and Reporting Software

In addition to the required patient demographics, include information about Cardea SOLO test indications, findings and implications for the patient's diagnosis and treatment plan:

Cardea SOLO Software Documentation	Approach
<b>Patient Demographic, Primary Indication and Patient Diary log sections</b>	Complete these fields to inform and enrich patient's clinical picture. Include any patient-reported events or symptoms experienced during testing
<b>Narrative Findings freeform text box section</b>	Include relevant clinician comments in addition to modifying and confirming content prior to clinician sign-off of Cardea SOLO report